Implementing HLA-B58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A...
Implementing HLA-B58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective
About this item
Full title
Author / Creator
Publisher
Public Library of Science (PLoS)
Journal title
Language
English
Formats
Publication information
Publisher
Public Library of Science (PLoS)
More information
Scope and Contents
Contents
IntroductionAllopurinol, the first-line treatment for chronic gout, is a common causative drug for severe cutaneous adverse reactions (SCAR). HLA-B*58:01 allele was strongly associated with allopurinol-induced SCAR in Asian countries such as Taiwan, Japan, Thailand and Malaysia. HLA-B*58:01 screening before allopurinol initiation is conditionally r...
Alternative Titles
Full title
Implementing HLA-B58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c8fc5defa2324bfeb6e2d4ea0a084b90
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c8fc5defa2324bfeb6e2d4ea0a084b90
Other Identifiers
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0296498
